undamentalytics Newsletter
Sign in

Xeris Biopharma Holdings, Inc. income statement

In fiscal 2025, Xeris Biopharma Holdings, Inc. reported revenue of $292m, up 43.7% on the year before, operating income of $24.9m (a 8.5% margin) and net income of $554,000, or $0.00 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue2050110164203292335
Research and development21252122263135
Selling, general and administrative74126138146163182208
Operating income−84−115−82−44−342537
Interest expense1171427302928
Income before tax—−123−96−64−571—
Income tax−00−1−1−200
Net income−91−123−95−62−551−17
Diluted EPS−$2.14−$1.55−$0.70−$0.45−$0.37$0.00−$0.09
Diluted shares (average)43m79m136m138m147m173m182m
EBITDA−82−114−81−43−322638

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: EOLS vs XERSIRWD vs XERSHROW vs XERSINVA vs XERS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Xeris Biopharma Holdings, Inc.